We are creating some awesome events for you. Kindly bear with us.

PolyU Develops Biomimetic Nanosheet for Cancer Therapy and Imaging

Image Credits: PolyU, Press Release
[social-share align="left" style="icon" size="m" template="18" counters="0" total_counter_pos="leftbig" buttons="linkedin,twitter,facebook,share"]

A research team from the Department of Applied Biology and Chemical Technology (ABCT) of The Hong Kong Polytechnic University (PolyU) has developed a novel type of biomimetic nanosheet with a multi-modal imaging function, which can track tumour development and treatment processes in real-time.

By harnessing two emerging cancer therapies, namely immunotherapy and photothermal therapy, the biomimetic nanosheet enables effective and precise treatment of tumours, which will significantly improve the therapeutic outcome of tumours, reduce side effects and increase patients’ survival rates. The research findings have been published in the prestigious international journal Advanced Science.

Professor Wing-tak WONG, Chair Professor of Chemical Technology of the ABCT of PolyU (also the Deputy President and Provost of PolyU), and his team started the research in 2018.

Synergistic therapy- Combining immunotherapy and photothermal therapy

New cancer treatments emerge since conventional cancer treatments like surgical therapy, chemotherapy and radiotherapy have different limitations and side effects.

Dr Summy Lo Wai-sum from ABCT said, “Immunotherapy and photothermal therapy are emerging methods which are expected to provide more options for cancer treatment. The biomimetic nanosheets developed by our team allow us to combine these two methods for synergistic therapy. By applying the synergistic therapy in an experiment for colorectal tumour treatment, we found that it is more effective than single therapy and has fewer side effects on the human body.”

The research team used 2D nanosheets (FePSe3) to develop a novel multifunctional nanomaterial for cancer theranostics. PD-1 (programmed cell death 1) exists on T cells, whereas PD-L1 (programmed cell death ligand-1) exists on tumour cells. Cancer cells inhibit the activation of the immune system and prevent T cells from attacking cancer cells through conjugating its PD-L1 with PD-1 on T cells.

The team, therefore, loaded the FePSe3 nanosheets with anti-PD-1 peptide (APP), which can block the conjugation between PD-1 on T-cells and PD-L1 on cancer cells to achieve efficient immunotherapy. Without directly attacking the cancer cells, blockage of the interaction between the PD-1 and PD-L1 has been reported to revoke T cell functions, leading to enhanced antitumour immunity.

After coating with cancer cell membranes, the nanosheets will become a biomimetic nanomaterial with tumour cell membrane characteristics that provide effective camouflage, enabling them to target the tumour site efficiently. Once the biomimetic nanosheets are injected into the living bodies, the cell membrane enveloping the nanosheets will preferentially adhere to cancer cells and slowly peel away, revealing the nanomaterial to begin immunotherapy.

Dr Lo explained, “The innate immune system attacks foreign objects which makes it difficult for the drug-loaded nanomaterials to reach the tumour site. The cancer cell membrane has a tumour-targeting characteristic that will converge homologous cells. It explains why the biomimetic nanosheets become attracted to the cancer cells when they are in close proximity with the cancer cells during blood circulation.

In addition, the large specific surface area of the 2D nanomaterials is conducive to improving the drug loading ratio of the anti-PD-1 peptide, which will help with enhancing the therapeutic efficiency, as well as reducing the drug dosage and hence alleviating side effects.”

On the other hand, the nanomaterials (FePSe3) chosen possess good photothermal conversion efficiency, and so they can convert near-infrared laser irradiation into heat to kill tumour cells directly, thus achieving effective photothermal therapy. The heat can further promote immunotherapy by effectively inhibiting tumour growth, which results in a synergistic effect of immunotherapy and photothermal therapy.

Three imaging modes to help real-time monitoring of cancer treatment

The PolyU-developed biomimetic nanosheets can also achieve the goals of theranostics. By harnessing magnetic, optical and thermal properties, the FePSe3 nanomaterials enable three imaging modalities, namely magnetic resonance imaging (MRI), photoacoustic imaging (PAI) and photothermal imaging (PTI), for real-time tracing and tracking of the tumour sites and the nanosheets, to achieve multimodal diagnosis in cancer treatment.

PolyU’s novel nanomaterial can facilitate theranostics by combining diagnosis, therapy and efficacy monitoring. It not only enables the imaging and treatment of tumours but also the real-time monitoring of treatment outcomes. The PolyU team carried out experiments on mice bearing subcutaneous colorectal tumours to investigate the application in living animals.

The study showed that the tumour volume had significantly reduced after 25 days of synergistic therapy, whereas the survival rate of the mice was three times higher than that of the control groups. The major organs of the mice, including the heart, liver, spleen, lung and kidney, showed no obvious inflammation and damage, demonstrating high biosafety and low toxicity.

The research team also utilised the MRI and photoacoustic imaging capabilities of the biomimetic nanosheet to observe the tumour for 24 hours, visualising the targeting and accumulation of the nano-theranostic material at the tumour site. Through photothermal imaging, it was observed that the nanomaterial can produce localised heat under near-infrared laser irradiation within a few minutes.

The experiment proved that PolyU-developed biomimetic nanosheets, with multi-modal imaging capability, can offer accurate and comprehensive detection and evaluation of tumour development, ultimately achieving theranostics alongside synergistic therapeutic effects.

Dr Lo said, “In view of the fact that there is a lack of efficient and safe theranostics materials, PolyU’s biomimetic nanomaterial has promising prospects in application. In future, our team will further expand the application of this nanomaterial to other cancer therapies and study the metabolism of the nanosheet in the living body, hoping that more cancer patients can benefit from new theranostic methods.”

[easy-social-share align="center" style="button" size="xxl" template="59" counters=0 noaffiliate="no" sidebar="no" popup="no" float="no" postfloat="no" topbar="no" bottombar="no" point="no" mobilebar="no" mobilebuttons="no" mobilepoint="no" facebook_text="Share on Facebook" linkedin_text="Share on LinkedIn" buttons="linkedin,facebook"]


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.